Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. G. Coleman
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients With Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy
Cancer immunology research
Cancer Research
Immunology
Related publications
P53 Expression Status Is Associated With Cancer-Specific Survival in Stage III and High-Risk Stage II Colorectal Cancer Patients Treated With Oxaliplatin-Based Adjuvant Chemotherapy
British Journal of Cancer
Cancer Research
Oncology
The CpG Island Methylator Phenotype May Confer a Survival Benefit in Patients With Stage II or III Colorectal Carcinomas Receiving Fluoropyrimidine-Based Adjuvant Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
PD-L1 Gene Expression in Japanese Lung Cancer Patients
Biomedical Reports
Genetics
Pharmacology
Molecular Biology
Biochemistry
Neuroscience
Medicine
Toxicology
Pharmaceutics
Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer
Clinical Medicine Insights: Oncology
Oncology
Serological Immune Response Against ADAM10 Pro-Domain Is Associated With Favourable Prognosis in Stage III Colorectal Cancer Patients
Oncotarget
Oncology
2-Year Single Center Clinical Experience in Patients With Colon Cancer Stage II and III Receiving Adjuvant Chemotherapy
Scripta Scientifica Medica
Clinical Predictive Value of in Vitro Anticancer Drug Sensitivity Test for the Therapeutic Effect of Adjuvant Chemotherapy in Patients With Stage II–III Colorectal Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
Adjuvant Chemotherapy of Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
P3.04-13 PD-L1-Gene Expression by nCounter Correlates With PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
